You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Computerizing NIAAA's Best Practices for Youth Screening and Brief Intervention
SBC: COG ANALYTICS, LLC Topic: 400DESCRIPTION provided by applicant The early onset of alcohol misuse during adolescence is a widespread problem in the U S Studies have consistently documented both the short and long term adverse neurophysiological impacts and health risk behaviors associated with alcohol misuse during adolescence Given the magnitude of this problem and its myriad consequences preventing early initiation of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing
SBC: TREVIGEN, INC. Topic: 113DESCRIPTION provided by applicant The objective of this Phase STTR research is to quantify genotoxicity in basal cell keratinocytes from organotypic cultures Epiderm in response to commonly used chemical agents The proposed product is a Comet Chip assay that measures DNA damage in basal cells derived from a reconstructed human epidermis Technical questions that will be addressed are Ca ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel therapies for inherited muscle diseases
SBC: Medosome Biotec, LLC Topic: NIAMSDESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development
SBC: QRKANSWER LLC Topic: NCIDESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to AD
SBC: MS Technologies Corporation Topic: NIAAlzheimer s Disease AD is the most common form of dementia and the sixth leading cause of death in the US More than million people in the US currently have AD and the direct health care cost is over $ billion per year Detection of early phase of AD namely Mild Cognitive Impairment MCI can delay prevent and treat this serious disease The project will develop a clinically feasible sy ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of peptide inhibitors for neuroinflammation and neurodegeneration
SBC: PROVAIDYA Topic: NIADESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Optimized AAV Serotype Vectors for Human Gene Therapy
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health